Radiotherapy With Adjuvant Durvalumab No Benefit for Head, Neck Cancer
No improvement seen in two-year progression-free survival for radiotherapy with durvalumab versus radiotherapy with cetuximab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.